Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Trial · NCT02072434
Adverse events212
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 212
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Atrial fibrillation | Cardiac disorders | Edoxaban | 53 | 1,067 | 53 |
| other | Atrial fibrillation | Cardiac disorders | Warfarin | 53 | 1,082 | 53 |
| serious | Hypertensive crisis | Vascular disorders | Edoxaban | 1 | 1,067 | 1 |
| serious | Hypertensive crisis | Vascular disorders | Warfarin | 1 | 1,082 | 1 |
| serious | Aortic aneurysm rupture | Vascular disorders | Edoxaban | 0 | 1,067 | 0 |
| serious | Aortic aneurysm rupture | Vascular disorders | Warfarin | 1 | 1,082 | 1 |
| serious | Deep vein thrombosis | Vascular disorders | Edoxaban | 1 | 1,067 | 1 |
| serious | Deep vein thrombosis | Vascular disorders | Warfarin | 0 | 1,082 | 0 |
| serious | Haemodynamic instability | Vascular disorders | Edoxaban | 1 | 1,067 | 1 |
| serious | Haemodynamic instability | Vascular disorders | Warfarin | 0 | 1,082 | 0 |
| serious | Peripheral artery thrombosis | Vascular disorders | Edoxaban | 0 | 1,067 | 0 |
| serious | Peripheral artery thrombosis | Vascular disorders | Warfarin | 1 | 1,082 | 1 |
| serious | Peripheral embolism | Vascular disorders | Edoxaban | 1 | 1,067 | 1 |
| serious | Peripheral embolism | Vascular disorders | Warfarin | 0 | 1,082 | 0 |
| serious | Thrombophlebitis | Vascular disorders | Edoxaban | 1 | 1,067 | 1 |
| serious | Thrombophlebitis | Vascular disorders | Warfarin | 0 | 1,082 | 0 |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Edoxaban | 1 | 1,067 | 1 |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Warfarin | 0 | 1,082 | 0 |
| serious | Non-small cell lung cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Edoxaban | 1 | 1,067 | 1 |
| serious | Non-small cell lung cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Warfarin | 0 | 1,082 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02072434/events